10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Cleaved-Caspase-5 p10 (S331) Polyclonal Antibody

Catalog # AP63105

Product Information

Application	WB, E
Primary Accession	P51878
Reactivity	Human, Rat, Mouse
Host	Rabbit
Clonality	Polyclonal
Calculated MW	49736

Additional Information

Gene ID	838
Other Names	CASP5; ICH3; Caspase-5; CASP-5; ICE(rel)-III; Protease ICH-3; Protease TY
Dilution	WB~~Western Blot: 1/500 - 1/2000. ELISA: 1/20000. Not yet tested in other applications. E~~N/A
Format	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium azide.
Storage Conditions	-20℃


Protein Information

Name	CASP5 {ECO:0000303|PubMed:16893518, ECO:0000312|HGNC:HGNC:1506}
Function	Thiol protease that acts as a mediator of programmed cell death (PubMed:28314590, PubMed:29898893). Initiates pyroptosis, a programmed lytic cell death pathway through cleavage of Gasdermin-D (GSDMD): cleavage releases the N-terminal gasdermin moiety (Gasdermin- D, N-terminal) that binds to membranes and forms pores, triggering pyroptosis (PubMed:29898893). Also mediates cleavage and maturation of IL18 (PubMed:37993714). Cleavage of GSDMD and IL18 is not strictly dependent on the consensus cleavage site but depends on an exosite interface on CASP4 (PubMed:37993714). During non-canonical inflammasome activation, cuts CGAS and may play a role in the regulation of antiviral innate immune activation (PubMed:28314590).
Tissue Location	Expressed in barely detectable amounts in most tissues except brain, highest levels being found in lung, liver and skeletal muscle.

Background

Mediator of programmed cell death (apoptosis). During non-canonical inflammasome activation, cuts CGAS and may play a role in the regulation of antiviral innate immune activation (PubMed:28314590).

Images



Western Blot analysis of various cells using Cleaved-Caspase-5 p10 (S331) Polyclonal Antibody diluted at 1：1000

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.